Precision Medicine
C3i bridges advanced translational research and clinical practice with our precision medicine services. We develop and implement companion diagnostics, therapeutic monitoring programs, and integrated patient support to help select the right treatment for the right patient and track outcomes throughout the therapeutic journey.
Our team of scientists, specialist physicians, health professionals, and laboratory experts work with pharmaceutical industry partners to design, validate, and operate precision medicine programs, from early biomarker discovery through clinical implementation in an accredited laboratory.
Precision medicine requires more than a great assay. It demands a partner who understands regulatory pathways, laboratory operations, clinical workflows, and the patient experience. C3i integrates all of these disciplines into programs that drive better therapeutic outcomes for patients.
Companion Diagnostic
A companion diagnostic (CDx) is a medical test that identifies which patients are most likely to benefit from a specific therapy.
C3i Precision Medicine Services are your end-to-end CDx partner: we design, validate, and implement testing programs in an accredited medical laboratory, whether you are developing a new drug, launching a biomarker strategy, or characterizing a specific disease population.
We are more than a service provider; we are your partner in diagnostic innovation, combining deep scientific expertise with the regulatory experience needed to implement clinical-grade assays. We support the following technologies on-site:
Immunoanalysis
- ELISA
- ELISPOT
- Multiplex assays (Luminex)
Molecular Genetics
- Sanger Sequencing
- MLPA
- NGS
- RT-qPCR
- Digital PCR
- Genotyping
Molecular Pathology
- Gene Expression
- NGS
- RT-PCR
- Immunohistochemistry
Additional Platforms
- Flow Cytometry
- Biochemistry
- STR (Genetic Identification)
Therapeutic Monitoring
Patient evolution requires advanced biomarker evaluation as well as assessment of immunogenicity that may be triggered by the treatment. Unlike molecular therapeutics, cell and gene therapies introduce new questions about efficacy and safety that traditional pharmacokinetic and pharmacodynamic monitoring alone cannot answer.
C3i’s immune and therapeutic monitoring service measures immune reconstitution, transplanted cell persistence, and therapy-related biomarkers, giving clinical teams and pharma partners the longitudinal data needed to assess and improve therapeutic outcomes for any kind of therapeutic approach.
Our Therapeutic Monitoring Service includes:
- Immune cell phenotyping
- Cytokine profiling and analysis
- Immune repertoire sequencing (TCRβ sequencing)
- Gene expression profiling: qPCR and digital PCR
- Biomarker analysis
- Chimerism analysis
- Therapeutic Drug Monitoring (TDM) and anti-drug antibody (ADA) testing
Whether you need a single assay or a comprehensive monitoring panel, our Therapeutic Monitoring Service delivers the laboratory expertise and clinical insight to overcome your most complex monitoring challenges.
Integrated Patient Support Programs
A validated test in an accredited laboratory is only the beginning. True precision medicine requires a continuous link between the patient, the prescribing physician, and the pharmaceutical partner. C3i designs and operates integrated patient support programs, personalized, end-to-end services that improve adherence, outcomes, and program intelligence for pharma partners.
Our team of scientists, specialist physicians, pharmacists, genetic counsellors, and dedicated patient care and account managers work together, backed by highly secured informatics tools customized to each partner’s needs and complying with all confidentiality requirements.
Our services include:
- National sample collection
- Appointment booking
- Adverse event reporting
- Physician support
- Genetic counselling
- Pharmacological guidance
- Custom program management reporting
C3i offers a comprehensive approach to personalized patient care, built around three core pillars:
- Through our Therapeutic Drug Monitoring (TDM) and Anti-Drug Antibody (ADA) testing programs, we ensure that treatments are both effective and safe by tracking drug levels and immunogenic responses.
- Our screening and diagnostic algorithms enable early detection, accurate patient stratification and therapeutic guidance, supporting more informed clinical decision-making.
- Finally, our pharmacogenomics programs leverage genetic insights to predict individual drug responses, helping clinicians tailor therapies to each patient’s unique biological profile.
Your Partner in Diagnostic Innovation
C3i brings together the scientific depth, clinical expertise, and operational infrastructure that precision medicine programs demand:
Accredited Laboratory
State-of-the-art, accredited medical laboratory infrastructure supporting clinical-grade diagnostics from assay development through patient testing.
Multidisciplinary Team
Scientists, specialist physicians, pharmacists, genetic counsellors, and patient care managers, all under one roof to ensure seamless program execution.
Pharma Partnership Model
We work as an extension of your team, aligning on timelines and program goals from the first conversation through commercial deployment and beyond.
Flexible Scope
From a single validated assay to a fully integrated national patient program, C3i scales its services to precisely meet your program requirements.
Complete Technology Portfolio
NGS, digital PCR, flow cytometry, immunohistochemistry, multiplex immunoassays, and more; all on-site, enabling rapid test development without external laboratory dependencies.
Patient-Centred Outcome
Every program is designed to improve therapeutic outcomes: linking testing, treatment decisions, and follow-up in a continuous loop of personalized care.
Answers about Precision Medicine at C3i
A companion diagnostic (CDx) is an in vitro diagnostic test that provides information essential for the safe and effective use of a corresponding therapeutic product. CDx tests identify patients whose biology, defined by a specific biomarker, gene mutation, or protein expression, makes them candidates for a targeted therapy. Regulatory agencies such as the FDA often require a validated CDx for the approval and labelling of certain drugs.
C3i develops and validates CDx tests in accredited medical laboratories, using technologies including NGS, immunoanalysis, molecular pathology, and flow cytometry, and can implement the testing program at a national scale through an integrated patient support infrastructure.
C3i offers three core precision medicine services:
- First, companion and complementary diagnostics: design, validation, and clinical implementation of CDx tests across a full range of laboratory platforms.
- Second, therapeutic monitoring: immune monitoring of cell and gene therapies through phenotyping, cytokine profiling, chimerism analysis, drug and anti-drug antibody monitoring and biomarker testing to follow the patient’s evolution.
- Third, integrated patient support programs: end-to-end patient programs that connect patients, physicians, and pharma partners throughout the treatment journey, including sample logistics, genetic counselling, and reporting.
C3i operates an accredited laboratory infrastructure with capabilities across six technology platforms: immunoanalysis (ELISA, ELISPOT, multiplex); molecular genetics (NGS, Sanger Sequencing, RT-qPCR, digital PCR, MLPA, genotyping); genetic identification (STR); molecular pathology (immunohistochemistry, NGS, RT-PCR, gene expression profiling); flow cytometry; and biochemistry.
All platforms are available on-site, enabling efficient test development and short turnaround times.
C3i designs integrated patient support programs as a connective layer between patients, prescribing physicians, and pharmaceutical partners.
From program enrollment through test result delivery, services include national sample collection logistics, appointment booking, adverse event reporting, direct physician support, genetic counselling, pharmacological guidance, and custom program management reporting.
Programs can be configured for TDM/ADA monitoring, patient screening and diagnostic algorithms, or pharmacogenomics testing to identify the optimal therapy for each patient.
C3i’s therapeutic monitoring service is designed for pharmaceutical partners developing or commercializing any kind of therapies.
The service measures immune reconstitution and transplanted cell persistence through immune cell phenotyping; cytokine profiling and analysis; immune repertoire sequencing (TCRβ sequencing); gene expression profiling (qPCR and digital PCR); biomarker analysis; chimerism analysis; and trough drug monitoring (TDM) combined with anti-drug antibody (ADA) testing.
Yes. C3i works with pharmaceutical and biotech companies and industry stakeholders, and positions itself as a strategic partner across the diagnostic innovation lifecycle.
From test design and biomarker validation through regulatory submission support, accredited laboratory implementation, and national patient program management, C3i’s multidisciplinary team of scientists, specialist physicians, pharmacists, and genetic counsellors becomes an extension of the pharma partner’s clinical and commercial team.